# Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

> **NCT00887107** · PHASE2 · COMPLETED · sponsor: **Leiden University Medical Center** · enrollment: 32 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Sorafenib (nexavar)

## Key facts

- **NCT ID:** NCT00887107
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2009-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00887107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00887107, "Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00887107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*